

MYOS RENS TECHNOLOGY INC.

Form 8-K

May 09, 2018

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**WASHINGTON, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the**

**Securities Exchange Act of 1934**

Date of Report (Date of earliest event reported): **May 9, 2018 (May 4, 2018)**

**MYOS RENS TECHNOLOGY INC.**

(Exact name of registrant as specified in its charter)

**Nevada**

(State or other jurisdiction  
of incorporation)

**000-53298**

(Commission File Number)

**90-0772394**

(IRS Employer

Identification No.)

**45 Horsehill Road,**

**07927**

**Suite 106 Cedar Knolls, New Jersey**

(Address of principal executive offices) (Zip Code)

Registrant's telephone number, including area code **(973) 509-0444**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

**Item 8.01. Other Events.**

On May 4, 2018, MYOS RENS Technology Inc. (the “**Company**”) entered into a research agreement with Weill Cornell Medical College to study the efficacy of Fortetropin® in preventing weight and muscle loss associated with cancer in a mouse model of lung cancer. The study will be led by Marcus Goncalves, MD, PhD, at Weill Cornell Medical College, and will use a genetically-engineered mice model of lung cancer in which mice develop cachexia characterized by reduced weight and lower muscle and fat mass. In this pre-clinical study, a cohort of adult mice will be induced with lung cancer. Five weeks after induction, 50% of mice will be switched to a Fortetropin®-infused diet and both groups will be monitored for changes in weight and food intake weekly for 8 weeks. After 8 weeks, the animals will be dissected for comparative analyses of body composition and skeletal muscle signaling between the two groups. The Company anticipates that the study will be completed and the results announced in the first quarter of 2019.

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**MYOS RENS  
TECHNOLOGY, INC.**

Dated: May 9, 2018 By: /s/ Joseph Mannello  
Name: Joseph Mannello  
Title: Chief Executive Officer